Market Overview:
The global vaccine conjugate market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of infectious diseases, increasing demand for preventive healthcare measures, and technological advancements in the vaccine conjugate industry. The global vaccine conjugate market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into Hib vaccine, meningococcal vaccine, pneumococcal vaccine, and others. The Hib vaccines segment is expected to account for the largest share of the global Vaccine Conjugate Market in 2018 owing to its high usage rates across all age groups. On the basis of application, children accounted for majority share in 2017 and it is projected that this trend will continue during forecast period as well due rising awareness about vaccination benefits among parents globally .
Product Definition:
A vaccine conjugate is a vaccine that has been chemically linked to an antigen from a pathogen. This linkage makes the vaccine more effective, as it allows for a longer exposure time to the antigen. Vaccine conjugates are also more stable than traditional vaccines, and can be stored at lower temperatures.
Hib Vaccine:
Hib vaccine is a live attenuated vaccines, which protects against Haemophilus influenzae type b. It's the most commonly recommended bacterial vaccine for children older than 3 months. The Centers for Disease Control and Prevention (CDC) recommends routine vaccination of children against HIB to avoid severe disease and its complications. Routine immunization of infants also reduces the incidence rate of severe disease in adults by 30%.
Meningococcal Vaccine:
Meningococcal vaccines are used to prevent meningitis and certain other forms of brain infection. The most commonly used vaccine is MenB (bivalent). It protects against both B and Y-shaped bacteria, which cause about 90% of all cases of meningitis.
Application Insights:
Based on the application, the global vaccine conjugate market is segmented into children and adult. The children segment held a major share in 2017 owing to growing usage of vaccines against chickenpox, measles, mumps, rubella and hepatitis A & B. Growing awareness regarding immunization against these diseases is expected to be a key factor driving growth over the forecast period.
The adult segment is expected to witness significant growth during the forecast period due to increasing use of vaccines for meningococcal disease and influenza among other diseases such as typhoid fever and cholera. Growing demand for preventive healthcare services along with high prevalence of chronic conditions such as cancer & autoimmune disorders that require regular check-ups are some other factors anticipated to boost demand over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of vaccine developers and manufacturers coupled with high healthcare expenditure levels in this region is expected to drive the demand for immunization products over the forecast period. Furthermore, increasing government initiatives pertaining to vaccination programs are also expected to propel industry growth over the coming years.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising awareness about vaccines among people as well as government support for immunization programs in emerging countries such as China and India. Moreover, growing target disease incidence rates are further anticipated boost product demand during the projected time frame. For instance, according to WHO statistics published on their website (2017), Japan witnessed an increase in SARS-CoV related cases which resulted into increased demand for meningococcal vaccines across this region resulting into higher revenue generation from Asia Pacific Vaccine Conjugate Market in 2017 compared with other regions’).
Growth Factors:
- Increasing incidence of infectious diseases: The increasing incidence of infectious diseases is one of the major growth drivers for the vaccine conjugate market. Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, and parasites. These infections can cause serious health problems and even death in some cases. According to the World Health Organization (WHO), there were about 1 million deaths due to tuberculosis in 2016, out of which about 480,000 were HIV-positive people co-infected with TB. In addition, there were an estimated 214 million cases of malaria worldwide in 2015, resulting in 438,000 deaths. The increasing incidence of these infectious diseases is expected to drive the demand for vaccine conjugates over the next few years.
- Growing awareness about preventive measures: There is a growing awareness among people regarding preventive measures against various infections and illnesses caused by pathogens such as bacteria and viruses. This has led to an increase in demand for vaccines that can help prevent these infections from occurring or spreading further. Vaccine conjugates are one such type of vaccine that helps protect individuals from various types of infection by targeting specific pathogens present within them.. This is expected to be a key driver for growth for the global vaccine conjugate market over the next few years
Scope Of The Report
Report Attributes
Report Details
Report Title
Vaccine Conjugate Market Research Report
By Type
Hib Vaccine, Meningococcal Vaccine, Pneumococcal Vaccine, Others
By Application
Children, Adult
By Companies
Pfizer, GSK, Sanofi, Merck, Walvax Biotechnology, Royal (Wuxi) Bio-Pharmaceutical, Bharat Biotech, Zhifei Biologic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
207
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Vaccine Conjugate Market Report Segments:
The global Vaccine Conjugate market is segmented on the basis of:
Types
Hib Vaccine, Meningococcal Vaccine, Pneumococcal Vaccine, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Children, Adult
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- GSK
- Sanofi
- Merck
- Walvax Biotechnology
- Royal (Wuxi) Bio-Pharmaceutical
- Bharat Biotech
- Zhifei Biologic
Highlights of The Vaccine Conjugate Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hib Vaccine
- Meningococcal Vaccine
- Pneumococcal Vaccine
- Others
- By Application:
- Children
- Adult
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Vaccine Conjugate Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A vaccine conjugate is a type of vaccine that uses a synthetic antigen, rather than the actual virus or bacteria. This makes it easier to create and produce, as well as more effective in preventing disease.
Some of the key players operating in the vaccine conjugate market are Pfizer, GSK, Sanofi, Merck, Walvax Biotechnology, Royal (Wuxi) Bio-Pharmaceutical, Bharat Biotech, Zhifei Biologic.
The vaccine conjugate market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Vaccine Conjugate Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Vaccine Conjugate Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Vaccine Conjugate Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Vaccine Conjugate Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Vaccine Conjugate Market Size & Forecast, 2018-2028
4.5.1 Vaccine Conjugate Market Size and Y-o-Y Growth
4.5.2 Vaccine Conjugate Market Absolute $ Opportunity
Chapter 5 Global Vaccine Conjugate Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Vaccine Conjugate Market Size Forecast by Type
5.2.1 Hib Vaccine
5.2.2 Meningococcal Vaccine
5.2.3 Pneumococcal Vaccine
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Vaccine Conjugate Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Vaccine Conjugate Market Size Forecast by Applications
6.2.1 Children
6.2.2 Adult
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Vaccine Conjugate Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Vaccine Conjugate Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Vaccine Conjugate Analysis and Forecast
9.1 Introduction
9.2 North America Vaccine Conjugate Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Vaccine Conjugate Market Size Forecast by Type
9.6.1 Hib Vaccine
9.6.2 Meningococcal Vaccine
9.6.3 Pneumococcal Vaccine
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Vaccine Conjugate Market Size Forecast by Applications
9.10.1 Children
9.10.2 Adult
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Vaccine Conjugate Analysis and Forecast
10.1 Introduction
10.2 Europe Vaccine Conjugate Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Vaccine Conjugate Market Size Forecast by Type
10.6.1 Hib Vaccine
10.6.2 Meningococcal Vaccine
10.6.3 Pneumococcal Vaccine
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Vaccine Conjugate Market Size Forecast by Applications
10.10.1 Children
10.10.2 Adult
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Vaccine Conjugate Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Vaccine Conjugate Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Vaccine Conjugate Market Size Forecast by Type
11.6.1 Hib Vaccine
11.6.2 Meningococcal Vaccine
11.6.3 Pneumococcal Vaccine
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Vaccine Conjugate Market Size Forecast by Applications
11.10.1 Children
11.10.2 Adult
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Vaccine Conjugate Analysis and Forecast
12.1 Introduction
12.2 Latin America Vaccine Conjugate Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Vaccine Conjugate Market Size Forecast by Type
12.6.1 Hib Vaccine
12.6.2 Meningococcal Vaccine
12.6.3 Pneumococcal Vaccine
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Vaccine Conjugate Market Size Forecast by Applications
12.10.1 Children
12.10.2 Adult
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Vaccine Conjugate Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Vaccine Conjugate Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Vaccine Conjugate Market Size Forecast by Type
13.6.1 Hib Vaccine
13.6.2 Meningococcal Vaccine
13.6.3 Pneumococcal Vaccine
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Vaccine Conjugate Market Size Forecast by Applications
13.10.1 Children
13.10.2 Adult
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Vaccine Conjugate Market: Competitive Dashboard
14.2 Global Vaccine Conjugate Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 GSK
14.3.3 Sanofi
14.3.4 Merck
14.3.5 Walvax Biotechnology
14.3.6 Royal (Wuxi) Bio-Pharmaceutical
14.3.7 Bharat Biotech
14.3.8 Zhifei Biologic
